Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4907710 | 0.90 | CSF1R (0.52) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL4914366 | 0.89 | CSF1R (0.56) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL4916739 | 0.84 | CSF1R (0.56) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL4912709 | 0.82 | CSF1R (0.53) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL4915059 | 0.81 | CSF1R (0.57) | CSF1REGFRERBB2 | |
| SCHEMBL4914335 | 0.81 | CSF1R (0.51) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL5930183 | 0.81 | CSF1R (0.52) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL4928955 | 0.79 | CSF1R (0.67) | CSF1RNUDT1EGFRERBB2 | |
| SCHEMBL5929958 | 0.79 | CSF1R (0.67) | CSF1RNUDT1EGFRERBB2 | |
| Trifluoroacetic Acid SCHEMBL4904588 | 0.78 | CSF1R (0.53) | CSF1RNUDT1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1718615-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075429-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | JAK3, JAK1, JAK2 | CSF1R 626/4885NUDT1 2876/4885EGFR 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.